HRP20220519T1 - Kombinacijska terapija ishemije - Google Patents
Kombinacijska terapija ishemije Download PDFInfo
- Publication number
- HRP20220519T1 HRP20220519T1 HRP20220519TT HRP20220519T HRP20220519T1 HR P20220519 T1 HRP20220519 T1 HR P20220519T1 HR P20220519T T HRP20220519T T HR P20220519TT HR P20220519 T HRP20220519 T HR P20220519T HR P20220519 T1 HRP20220519 T1 HR P20220519T1
- Authority
- HR
- Croatia
- Prior art keywords
- psd
- inhibitor
- ischemia
- intended
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Dermatology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (18)
1. Inhibitor PSD-95, naznačen time što je namijenjen upotrebi u liječenju oštećujućeg učinka ishemije na središnji živčani sustav kod subjekta koji ima ili je u opasnosti od ishemije, gdje se reperfuzijsku terapiju provodi na subjektu, a inhibitor PSD-95 i reperfuzijska terapija liječe oštećujući učinak ishemije na središnji živčani sustav subjekta, te gdje se reperfuzijska terapija sastoji u primjeni trombolitičkog sredstva, gdje inhibitor PSD-95 sadrži peptid koji sadrži SEQ ID NO:38 na C-kraju, ili sadrži SEQ ID NO:68, gdje je peptid vezan na internalizirajući peptid ili je lipidiran, čime se pojačava prolazak peptida preko membrane ili krvno-moždane barijere.
2. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se inhibitor PSD-95 primjenjuje kada se sumnja na inzult ili koje drugo ishemijsko stanje bez postavljanja dijagnoze u skladu s kriterijima prepoznatima u struci.
3. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se primjenjuje unutar 15 minuta nakon trombolitičkog sredstva.
4. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen primjeni u više doza dok se ne detektira prisutnost potpunog infarkta prilikom CT skeniranja ili dok se ne vidi nikakva daljnja dobrobit.
5. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je oštećujući učinak ishemije infarkt ili funkionalni nedostatak.
6. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se inhibitor PSD-95 primjenjuje prije provođenja reperfuzijske terapije, ili se inhibitor PSD-95 primjenjuje na subjektu u opasnosti od ishemije prije početka ishemije i provođenje reperfuzijske terapije nakon početka ishemije, ili se inhibitor PSD-95 primjenjuje i reperfuzijsku terapiju provodi nakon početka ishemije.
7. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je ishemija cerebralna ishemija, ili što subjekt ima inzult, ili što je ishemija srčana, plućna ili velika ishemija udova, koja pogađa središnji živčani sustav inhibiranjem krvotoka u ili iz CNS-a.
8. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se subjekta testira na prisutnost cerebralne ishemije i/ili odsutnost cerebralnog krvarenja između primjene inhibitora PSD-95 i provođenja reperfuzijske terapije, ili što se subjekta procjenjuje na prisutnost ili opasnost od krvarenja između primjene inhibitora PSD-95 i provođenja reperfuzijske terapije, izborno što procjenjivanje uključuje provođenje PET skeniranja, CAT skeniranja, MRI, ili pregledavanje povijesti subjektove bolesti, ili upotrebu jednog ili više bioloških biljega koji ukazuju na ishemiju.
9. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je inhibitor PSD-95 vezan na internalizirajući peptid Tat kako bi tvorio Tat-NR2B9c.
10. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je trombolitičko sredstvo aktivator plazminogena.
11. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je trombolitičko sredstvo tPA, primjerice alteplaza, reteplaza ili tenekteplaza.
12. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je trombolitičko sredstvo streptokinaza, urokinaza, ili dezmotaplaza.
13. Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 9-12, naznačen time što je interval između primjene inhibitora PSD-95 i reperfuzijske terapije 30 minuta do 6 sati, ili što se reperfuzijsku terapiju provodi više od 3 sata nakon početka ishemije.
14. Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 9-13, naznačen time što se trombolitičko sredstvo primjenjuje lokaliziranom primjenom na mjestu smanjenog krvotoka, ili što se reperfuzijsku terapiju provodi više od 3 sata nakon početka ishemije, što se reperfuzijsku terapiju izborno provodi više od 4,5 sati nakon početka ishemije, ili što se reperfuzijsku terapiju provodi više od 4,5 sati, a manje od 24 sata nakon početka ishemije.
15. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što provođenje reperfuzijske terapije nakon određivanja ima li kod subjekta razloga za reperfuziju na osnovi neočitovanja potpunog infarkta, ishemijske penumbre i neočitovanja krvarenja prilikom CT, MRI ili PET analize, ili što se reperfuzijsku terapiju provodi najmanje 12 ili najmanje 24 sata nakon početka ishemije, ili što se reperfuzijsku terapiju provodi 275-690 minuta nakon početka ishemije.
16. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je peptid lipidiran kao miristoilirani peptid, što pojačava prolazak peptida preko stanične membrane ili krvno-moždane barijere.
17. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 16, naznačen time što peptid ima aminokiselina slijed koji se sastoji od ili sadrži KLSSIESDV (SEQ ID NO:5) ili KLSSIETDV (SEQ ID NO:43), izborno miristoiliran na N-kraju peptida.
18. Trombolitičko sredstvo, naznačeno time što je namijenjeno upotrebi u reperfuzijskoj terapiji kod subjekta koji također prima inhibitor PSD-95, gdje reperfuzijska terapija i sredstvo liječe oštećujući učinak ishemije na središnji živčani sustav, gdje inhibitor PSD-95 sadrži peptid koji sadrži SEQ ID NO:38 na C-kraju, ili sadrži SEQ ID NO:68, gdje je peptid vezan na internalizirajući peptid ili je lipidiran, čime se pojačava prolazak peptida preko membrane ili krvno-moždane barijere.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501117P | 2011-06-24 | 2011-06-24 | |
| US201261617001P | 2012-03-28 | 2012-03-28 | |
| EP18190827.8A EP3427748B1 (en) | 2011-06-24 | 2012-06-23 | Combination therapy for ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220519T1 true HRP20220519T1 (hr) | 2022-05-27 |
Family
ID=47423033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220519TT HRP20220519T1 (hr) | 2011-06-24 | 2012-06-23 | Kombinacijska terapija ishemije |
| HRP20181526TT HRP20181526T1 (hr) | 2011-06-24 | 2018-09-25 | Kombinacijska terapija ishemije |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181526TT HRP20181526T1 (hr) | 2011-06-24 | 2018-09-25 | Kombinacijska terapija ishemije |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10064910B2 (hr) |
| EP (3) | EP2723363B1 (hr) |
| JP (5) | JP6401057B2 (hr) |
| KR (5) | KR102022116B1 (hr) |
| CN (1) | CN103648518B (hr) |
| AU (1) | AU2012274910B2 (hr) |
| CA (1) | CA2839630A1 (hr) |
| CY (1) | CY1121379T1 (hr) |
| DK (2) | DK2723363T3 (hr) |
| ES (2) | ES2912042T3 (hr) |
| HR (2) | HRP20220519T1 (hr) |
| HU (2) | HUE058238T2 (hr) |
| LT (1) | LT2723363T (hr) |
| PL (2) | PL2723363T3 (hr) |
| PT (2) | PT2723363T (hr) |
| RS (1) | RS57798B1 (hr) |
| SI (1) | SI2723363T1 (hr) |
| SM (1) | SMT201800592T1 (hr) |
| WO (1) | WO2012176172A2 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2847293T3 (es) | 2009-06-10 | 2021-08-02 | Nono Inc | Regímenes de tratamiento para el tratamiento de enfermedades neurológicas |
| PT2723363T (pt) | 2011-06-24 | 2018-11-08 | Nono Inc | Terapia de combinação para isquemia |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| CZ2012476A3 (cs) * | 2012-07-12 | 2014-01-22 | Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. | Lipidované peptidy jako antiobezitika |
| US10220008B2 (en) | 2013-08-14 | 2019-03-05 | Stc.Unm | Treatment and prevention of stroke and other neurological disorders |
| WO2015080859A1 (en) * | 2013-11-26 | 2015-06-04 | Trustees Of Dartmouth College | Method for mitigating or alleviating synaptic and cognitive deficits |
| FR3021319B1 (fr) * | 2014-05-22 | 2018-08-31 | Sederma | Peptides, compositions les comprenant et utilisations notamment cosmetiques |
| CZ309217B6 (cs) * | 2014-05-27 | 2022-06-01 | Ústav Organické Chemie A Biochemie Av Čr, V.V.I. | Lipidované peptidy jako neuroprotektiva |
| WO2015181756A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Chloride salt of tat-nr2b9c |
| US9526768B2 (en) | 2014-11-13 | 2016-12-27 | Jennifer Mai | Compositions for the treatment of cancer |
| CN104497106B (zh) * | 2014-12-05 | 2017-05-10 | 华中科技大学 | 一种小分子多肽、其应用及产品 |
| CN107312069B (zh) * | 2016-04-27 | 2018-11-06 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽 |
| EP3450448B1 (en) * | 2016-04-27 | 2021-04-07 | Biocells (Beijing) Biotech Co., Ltd. | Therapeutic peptide for excitatory neurotoxicity-related injuries |
| EP3450446A1 (en) * | 2016-04-27 | 2019-03-06 | Biocells (Beijing) Biotech Co., Ltd. | Treatment method for excitatory neurotoxicity-related injury |
| CN107446016A (zh) * | 2016-05-30 | 2017-12-08 | 上海交通大学 | 一种硬脂酸修饰的细胞穿膜肽及其制备与应用 |
| CN106265594B (zh) * | 2016-09-21 | 2019-07-26 | 南京医科大学 | 一种缺血性脑卒中靶向的红细胞膜仿生智能药物载体及其制备方法 |
| CN106749559B (zh) * | 2016-11-23 | 2020-09-04 | 郑州大学 | 一种基于细胞穿膜肽Tat(49-57)的抗菌肽及其合成方法 |
| JP7109958B2 (ja) * | 2017-04-04 | 2022-08-01 | キヤノンメディカルシステムズ株式会社 | 磁気共鳴イメージングシステム、磁気共鳴イメージング装置、及び磁気共鳴イメージング方法 |
| JP7002788B2 (ja) * | 2017-07-05 | 2022-03-03 | 拜西欧斯（北京）生物技術有限公司 | ポリペプチドの薬学的に許容される塩およびその使用 |
| CN110799522B (zh) * | 2017-07-05 | 2023-08-29 | 拜西欧斯（北京）生物技术有限公司 | 用于治疗、改善或预防脑出血的肽及其用途 |
| JP7073486B2 (ja) * | 2017-09-30 | 2022-05-23 | ▲拝▼西欧斯（北京）生物技▲術▼有限公司 | 興奮性神経毒性に関連した損傷の治療用ペプチド組成物 |
| US12122811B2 (en) | 2018-04-06 | 2024-10-22 | Northwestern University | BDNF mimetic peptide amphiphiles |
| JP7158904B2 (ja) * | 2018-06-14 | 2022-10-24 | 社会福祉法人 恩賜財団済生会熊本病院 | 治療方針決定支援装置、治療方針決定支援装置の作動方法、および治療方針決定支援プログラム |
| WO2021165891A1 (en) * | 2020-02-19 | 2021-08-26 | Nono Inc. | Inhibition of reperfusion injury with a psd-95 inhibitor |
| KR20220143714A (ko) * | 2020-02-19 | 2022-10-25 | 노노 인코포레이티드 | 플라스민-절단 가능한 psd-95 억제제 및 재관류로의 뇌졸중의 병용 치료 |
| CN113735938B (zh) * | 2021-07-30 | 2024-11-08 | 英纳氏(珠海)药业有限公司 | 一种神经保护多肽化合物及其应用 |
| WO2023192848A1 (en) * | 2022-03-28 | 2023-10-05 | University Of Maryland, Baltimore | Methods and compositions for the treatment of stroke |
| CN117422722B (zh) * | 2023-12-19 | 2024-03-29 | 北京智源人工智能研究院 | 基于adc图像的肿瘤预后特征评估的方法和装置 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2742152B1 (fr) | 1995-12-06 | 1998-01-16 | Synthelabo | Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique |
| US6562345B1 (en) | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6903184B1 (en) | 1998-03-02 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multiple antigenic peptides immunogenic against Streptococcus pneumonia |
| US20060148711A1 (en) | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
| US20070123567A1 (en) | 2003-04-25 | 2007-05-31 | Mitos Pharmaceuticals Inc. | Prophylactic pretreatment with antioxidants |
| CA2524573A1 (en) | 2003-05-02 | 2004-11-11 | Paion Deutschland Gmbh | Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke |
| BRPI0410470A (pt) * | 2003-05-19 | 2006-06-20 | Kenneth S Warren Inst Inc | uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente |
| TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| JP5746468B2 (ja) * | 2006-07-11 | 2015-07-08 | ノノ インコーポレイテッド | 発熱を伴う脳卒中を処置する方法および組成物 |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| CU23630A1 (es) | 2006-10-30 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae |
| JP5631595B2 (ja) * | 2007-03-02 | 2014-11-26 | ノノ インコーポレイテッド | Ｎ型カルシウムチャネルを阻害せずに卒中および他の疾患を治療する方法 |
| GB0707348D0 (en) | 2007-04-17 | 2007-05-23 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| WO2009006611A1 (en) | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| PL2205623T3 (pl) | 2007-10-29 | 2016-09-30 | Ochronne tetrapeptydy do pielęgnacji skóry | |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| JP5727792B2 (ja) | 2008-01-25 | 2015-06-03 | オーフス ユニバーシテ | Ｉｇｆｂｐ−４に対するｐａｐｐ−ａ活性の選択的エキソサイト阻害 |
| US9241967B2 (en) | 2008-07-09 | 2016-01-26 | University Of Copenhagen | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction |
| DE102008037564A1 (de) | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| CA2665302A1 (en) | 2009-05-01 | 2010-11-01 | Universite De Montreal | Cd36 modulation and uses thereof |
| EP3682895A1 (en) | 2009-06-10 | 2020-07-22 | NoNO Inc. | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
| ES2847293T3 (es) | 2009-06-10 | 2021-08-02 | Nono Inc | Regímenes de tratamiento para el tratamiento de enfermedades neurológicas |
| US20110144029A1 (en) | 2009-09-30 | 2011-06-16 | Board Of Regents, The University Of Texas System | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases |
| PT2723363T (pt) | 2011-06-24 | 2018-11-08 | Nono Inc | Terapia de combinação para isquemia |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| WO2013088382A1 (en) | 2011-12-13 | 2013-06-20 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
-
2012
- 2012-06-23 PT PT12802409T patent/PT2723363T/pt unknown
- 2012-06-23 SI SI201231412T patent/SI2723363T1/sl unknown
- 2012-06-23 AU AU2012274910A patent/AU2012274910B2/en active Active
- 2012-06-23 HU HUE18190827A patent/HUE058238T2/hu unknown
- 2012-06-23 SM SM20180592T patent/SMT201800592T1/it unknown
- 2012-06-23 HR HRP20220519TT patent/HRP20220519T1/hr unknown
- 2012-06-23 DK DK12802409.8T patent/DK2723363T3/en active
- 2012-06-23 HU HUE12802409A patent/HUE040564T2/hu unknown
- 2012-06-23 PT PT181908278T patent/PT3427748T/pt unknown
- 2012-06-23 DK DK18190827.8T patent/DK3427748T3/da active
- 2012-06-23 KR KR1020147001639A patent/KR102022116B1/ko active Active
- 2012-06-23 ES ES18190827T patent/ES2912042T3/es active Active
- 2012-06-23 KR KR1020197026571A patent/KR102140169B1/ko active Active
- 2012-06-23 EP EP12802409.8A patent/EP2723363B1/en active Active
- 2012-06-23 WO PCT/IB2012/053178 patent/WO2012176172A2/en active Application Filing
- 2012-06-23 RS RS20181182A patent/RS57798B1/sr unknown
- 2012-06-23 KR KR1020217026955A patent/KR102425466B1/ko active Active
- 2012-06-23 EP EP18190827.8A patent/EP3427748B1/en active Active
- 2012-06-23 JP JP2014516487A patent/JP6401057B2/ja active Active
- 2012-06-23 PL PL12802409T patent/PL2723363T3/pl unknown
- 2012-06-23 EP EP22157256.3A patent/EP4052721A1/en not_active Withdrawn
- 2012-06-23 US US14/128,941 patent/US10064910B2/en active Active
- 2012-06-23 PL PL18190827T patent/PL3427748T3/pl unknown
- 2012-06-23 KR KR1020227025470A patent/KR20220106862A/ko active Pending
- 2012-06-23 CN CN201280031302.4A patent/CN103648518B/zh active Active
- 2012-06-23 CA CA2839630A patent/CA2839630A1/en active Pending
- 2012-06-23 KR KR1020207021829A patent/KR102296106B1/ko active Active
- 2012-06-23 LT LTEP12802409.8T patent/LT2723363T/lt unknown
- 2012-06-23 ES ES12802409.8T patent/ES2690994T3/es active Active
-
2017
- 2017-04-05 JP JP2017074975A patent/JP2017193535A/ja active Pending
-
2018
- 2018-08-01 US US16/051,971 patent/US10967041B2/en active Active
- 2018-09-25 HR HRP20181526TT patent/HRP20181526T1/hr unknown
- 2018-10-30 JP JP2018204034A patent/JP7085457B2/ja active Active
- 2018-11-28 CY CY20181101260T patent/CY1121379T1/el unknown
-
2020
- 2020-08-06 JP JP2020134150A patent/JP7143374B2/ja active Active
-
2021
- 2021-02-17 US US17/177,970 patent/US11878044B2/en active Active
-
2022
- 2022-09-14 JP JP2022146191A patent/JP2022188068A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220519T1 (hr) | Kombinacijska terapija ishemije | |
| Fröhlich et al. | Myocardial reperfusion injury: looking beyond primary PCI | |
| Hausenloy et al. | Myocardial ischemia-reperfusion injury: a neglected therapeutic target | |
| Wasserman et al. | Minocycline protects the blood–brain barrier and reduces edema following intracerebral hemorrhage in the rat | |
| Keep et al. | Blood-brain barrier function in intracerebral hemorrhage | |
| JP2014520142A5 (hr) | ||
| HRP20201973T1 (hr) | Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti | |
| Savitz et al. | Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials | |
| Gauberti et al. | Thrombolytic strategies for ischemic stroke in the thrombectomy era | |
| UA112985C2 (uk) | Одноланцюговий поліпептидний гібридний білок | |
| JP2012523438A5 (hr) | ||
| JP2014511698A5 (hr) | ||
| Sun et al. | PDGF-BB-induced MT1-MMP expression regulates proliferation and invasion of mesenchymal stem cells in 3-dimensional collagen via MEK/ERK1/2 and PI3K/AKT signaling | |
| WO2009126349A3 (en) | Methods and compositions related to internalizing rgd peptides | |
| Sonni et al. | New avenues for treatment of intracranial hemorrhage | |
| Singh et al. | Valproic acid in prevention and treatment of COVID-19 | |
| Jeong et al. | Neuroprotective effect of PEP-1-peroxiredoxin2 on CA1 regions in the hippocampus against ischemic insult | |
| Elbadawi et al. | Impact of remote ischemic postconditioning during primary percutaneous coronary intervention on left ventricular remodeling after anterior wall ST-segment elevation myocardial infarction: a single-center experience | |
| CN101015686B (zh) | 一种溶栓药物增效剂及其制备方法 | |
| Yu et al. | 2-(4-methoxyphenyl) ethyl-2-acetamido-2-deoxy-β-d-pyranoside (a salidroside analog) confers neuroprotection with a wide therapeutic window by regulating local glucose metabolism in a rat model of cerebral ischemic injury | |
| CN102268069B (zh) | 基质金属蛋白酶-9多肽抑制剂4及其应用 | |
| Bosch | Carvedilol for preventing recurrent variceal bleeding: waiting for convincing evidence | |
| CN102268070B (zh) | 基质金属蛋白酶-9多肽抑制剂2及其应用 | |
| Tanaka et al. | Serum S100B indicates successful combination treatment with recombinant tissue plasminogen activator and MK-801 in a rat model of embolic stroke | |
| Barrère-Lemaire et al. | Delayed postconditioning: not too late? |